A novel prognostic nomogram for colorectal cancer liver metastasis patients with recurrence after hepatectomy

被引:12
|
作者
Liang, Jie-ying [1 ,2 ]
Lin, Hao-cheng [1 ,2 ]
Liu, Jingwen [3 ]
Wang, De-shen [1 ,2 ]
Yuan, Yun-fei [1 ,4 ]
Li, Bin-kui [1 ,4 ]
Zheng, Yun [1 ,4 ]
Wu, Xiao-jun [1 ,5 ]
Chen, Gong [1 ,5 ]
Wang, Feng-hua [1 ,2 ]
Wang, Zhi-qiang [1 ,2 ]
Pan, Zhi-zhong [1 ,5 ]
Wan, De-sen [1 ,5 ]
Xu, Rui-hua [1 ,2 ]
Li, Yu-hong [1 ,2 ]
机构
[1] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Zhongshan Sch Med, Guangzhou, Peoples R China
[4] Sun Yat Sen Univ, Ctr Canc, Dept Hepatobiliary Surg, Guangzhou, Peoples R China
[5] Sun Yat Sen Univ, Ctr Canc, Dept Colorectal Surg, Guangzhou, Peoples R China
来源
CANCER MEDICINE | 2021年 / 10卷 / 05期
关键词
colorectal cancer liver metastasis; hepatectomy; nomogram; post‐ recurrence survival; prognostic factors; HEPATIC RESECTION; REPEAT RESECTION; SURVIVAL; MANAGEMENT; ABLATION; MARGIN;
D O I
10.1002/cam4.3697
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose We aimed to construct a nomogram to predict personalized post-recurrence survival (PRS) among colorectal cancer liver metastasis (CRLM) patients with post-hepatectomy recurrence. Methods Colorectal cancer liver metastasis patients who received initial hepatectomy and had subsequent recurrence between 2001 and 2019 in Sun Yat-sen University Cancer Center from China were included in the study. Patients were randomly assigned to a training cohort and a validation cohort on a ratio of 2:1. Univariable analysis was first employed to select potential predictive factors for PRS. Then, the multivariable Cox regression model was applied to recognize independent prognostic factors. According to the model, a nomogram to predict PRS was established. The nomogram's predictive capacity was further assessed utilizing concordance index (C-index) values, calibration plots, and Kaplan-Meier curves. Results About 376 patients were finally enrolled, with a 3-year PRS rate of 37.3% and a 5-year PRS rate of 24.6%. The following five independent predictors for PRS were determined to construct the nomogram: the largest size of liver metastases at initial hepatectomy, relapse-free survival, CEA level at recurrence, recurrent sites, and treatment for recurrence. The nomogram displayed fairly good discrimination and calibration. The C-index value was 0.742 for the training cohort and 0.773 for the validation cohort. Patients were grouped into three risk groups very well by the nomogram, with 5-year PRS rates of 45.2%, 23.3%, and 9.0%, respectively (p < 0.001) in the training cohort and 36.0%, 9.2%, and 4.6%, respectively (p < 0.001) in the validation cohort. Conclusion A novel nomogram was built and validated to enable the prediction of personal PRS in CRLM patients with post-hepatectomy recurrence. The nomogram may help physicians in decision making.
引用
收藏
页码:1535 / 1544
页数:10
相关论文
共 50 条
  • [1] Development of a novel prognostic nomogram for the early recurrence of liver cancer after curative hepatectomy
    Xia, Wuzheng
    Peng, Tianyi
    Guan, Renguo
    Zhou, Yu
    Zeng, Cong
    Lin, Ye
    Wu, Zhongshi
    Tan, Hongmei
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (20)
  • [2] TREATMENT FOR RECURRENCE AFTER HEPATECTOMY IN PATIENTS WITH COLORECTAL LIVER METASTASIS
    Miyagawa, S.
    Yokoyama, T.
    ANNALS OF ONCOLOGY, 2010, 21 : 206 - 206
  • [3] Clinicopathological analysis of recurrence patterns and prognostic factors for survival after hepatectomy for colorectal liver metastasis
    Michihiro Hayashi
    Yoshihiro Inoue
    Koji Komeda
    Tetsunosuke Shimizu
    Mitsuhiro Asakuma
    Fumitoshi Hirokawa
    Yoshiharu Miyamoto
    Junji Okuda
    Atsushi Takeshita
    Yuro Shibayama
    Nobuhiko Tanigawa
    BMC Surgery, 10
  • [4] Clinicopathological analysis of recurrence patterns and prognostic factors for survival after hepatectomy for colorectal liver metastasis
    Hayashi, Michihiro
    Inoue, Yoshihiro
    komeda, Koji
    Shimizu, Tetsunosuke
    Asakuma, Mitsuhiro
    Hirokawa, Fumitoshi
    Miyamoto, Yoshiharu
    Okuda, Junji
    Takeshita, Atsushi
    Shibayama, Yuro
    Tanigawa, Nobuhiko
    BMC SURGERY, 2010, 10
  • [5] Prognostic Impact of Budding Grade in Patients With Residual Liver Recurrence of Colorectal Cancer After Initial Hepatectomy
    Takuji Noro
    Makoto Nishikawa
    Mayumi Hoshikawa
    Takahiro Einama
    Suefumi Aosasa
    Yoshiki Kajiwara
    Yoshihisa Yaguchi
    Koichi Okamoto
    Eiji Shinto
    Hironori Tsujimoto
    Kazuo Hase
    Hideki Ueno
    Junji Yamamoto
    Annals of Surgical Oncology, 2020, 27 : 5200 - 5207
  • [6] Prognostic Impact of Budding Grade in Patients With Residual Liver Recurrence of Colorectal Cancer After Initial Hepatectomy
    Noro, Takuji
    Nishikawa, Makoto
    Hoshikawa, Mayumi
    Einama, Takahiro
    Aosasa, Suefumi
    Kajiwara, Yoshiki
    Yaguchi, Yoshihisa
    Okamoto, Koichi
    Shinto, Eiji
    Tsujimoto, Hironori
    Hase, Kazuo
    Ueno, Hideki
    Yamamoto, Junji
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (13) : 5200 - 5207
  • [7] A novel gene signature that predicts recurrence following hepatectomy in patients with colorectal liver metastasis.
    Wada, Yuma
    Shimada, Mitsuo
    Goel, Ajay
    CANCER RESEARCH, 2021, 81 (13)
  • [8] Hepatectomy for liver metastasis of colorectal cancer
    Xu, Jianmin
    Wei, Ye
    Zhong, Yunshi
    Fan, Jia
    Zhou, Jian
    Qin, Lunxiu
    Ren, Li
    Qin, Xinyu
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2009, 24 (04) : 419 - 425
  • [9] Hepatectomy for liver metastasis of colorectal cancer
    Jianmin Xu
    Ye Wei
    Yunshi Zhong
    Jia Fan
    Jian Zhou
    Lunxiu Qin
    Li Ren
    Xinyu Qin
    International Journal of Colorectal Disease, 2009, 24 : 419 - 425
  • [10] A Comprehensive Prognostic Model for Colorectal Cancer Liver Metastasis Recurrence After Neoadjuvant Chemotherapy
    Zhou, Zhenyuan
    Han, Xin
    Sun, Diandian
    Liang, Zhiying
    Wu, Wei
    Ju, Haixing
    FRONTIERS IN ONCOLOGY, 2022, 12